- **Prilenia and Ferrer** announced the presentation of new 2-year data for pridopidine at the 2025 HSG HD Clinical Research Congress, demonstrating **significant and clinically meaningful slowing of progression** in Huntington's Disease (HD) patients not taking antidopaminergic medicines (ADMs).  **[1678660_9e6f31f89b3f41719ab040b88e07abf3_0]** 
- The data showed slowing of progression by **65%** for TFC and **59%** for cUHDRS, **88%** for cognition (SWR), and **78%** for motor features (Q-Motor) for pridopidine-treated patients off ADMs over 2 years.  **[1678660_9e6f31f89b3f41719ab040b88e07abf3_2]** 
- A global confirmatory clinical trial for pridopidine in early-stage HD patients is planned to commence in the **first half of 2026**.  **[1678660_9e6f31f89b3f41719ab040b88e07abf3_0]** **[1678660_9e6f31f89b3f41719ab040b88e07abf3_1]** 
- Pridopidine has received **Orphan Drug Designation** in HD and ALS in the US and EU, and **FDA Fast Track Designation** for the treatment of HD.  **[1678660_9e6f31f89b3f41719ab040b88e07abf3_3]**

Prelude Therapeutics (PRLD)